Inhibitors of bone calcium resorption are administered to allow high doses of vitamin D compounds or mimetics to be given with the intent of treating non-calcium related diseases such as cancer, psoriasis, and autoimmune disease without the dangers of calcification of kidney, heart, and aorta. Inhibitors of bone calcium resorption include the bis-phosphonates, OPG (osteoprotegerin) or the soluble RANKL (receptor activator of NF-.kappa.B ligand) receptor known as sRANK (soluble RANK which is the protein expressed by the NF-.kappa.B gene), and function to block the availability of calcium from bone thereby preventing hypercalcemia and the resulting calcification of soft tissues. Thus, high doses of 1.alpha.,25-dihydroxyvitamin D.sub.3 (1,25-(OH).sub.2D.sub.3), its analogs, prodrugs, or mimetics can be utilized with minimal risk to a patient. Specifically, alendronate is shown to block the bone calcium mobilization activity of both 1,25-(OH).sub.2D.sub.3 and its very potent analog, 2-methylene -19-nor-(20S)-1.alpha.,25-dihydroxyvitamin D.sub.3.